Literature DB >> 34427253

Evaluating the presence of SARS-CoV-2 in the intraocular fluid of COVID-19 patients.

Maya Hada1, Kamlesh Khilnani1, Nitya Vyas2, Jugal Kishore Chouhan1, Kulveer S Dharawat1, Sudhir Bhandari3, Koushik Tripathy4.   

Abstract

PURPOSE: To detect the presence of SARS-CoV-2 in aqueous and vitreous humor of COVID-19 patients in a pilot study.
METHODS: : Consecutive patients planned for emergency ophthalmic surgeries after ocular trauma were subjected to naso-oropharyngeal RT-PCR test for SARS-CoV-2. Laboratory-confirmed cases were enrolled for the study. During surgery, 0.1 mL aqueous and vitreous each was aspirated. The vitreous tap was collected on clinical suspicion of endophthalmitis. RT-PCR test was used to detect SARS-COV-2 nucleotide in the samples. Cycle threshold (Ct) for E gene of ≤35 along with confirmatory results on one of the two target genes (RdRp or ORF1b) was considered as positive.
RESULTS: : One hundred and thirty two patients were found positive on naso-oropharyngeal RT-PCR test for SARS-CoV-2 preoperatively. Seven patients with ocular trauma were studied. The mean age was 31.8 years. There were six male and one female patient. Two patients had symptoms of mild COVID-19 disease and the rest were asymptomatic. The mean Ct value of the E gene on naso-oropharyngeal RT-PCR was 23.14 ± 4.7. Corneal and corneoscleral laceration repair was done in five patients, intracorneal wooden foreign body was removed in one patient, and injection of intravitreal antibiotics was done in one patient. Aqueous and vitreous tap was collected in 7 and 5 patients, respectively. None of the aqueous or vitreous samples was found positive for SARS-CoV-2.
CONCLUSION: : SARS-CoV-2 was not detected by RT-PCR in aqueous or vitreous humor in this pilot study. Future studies with a larger sample size are needed to further explore the presence of SARS-CoV-2 in intraocular fluids.

Entities:  

Keywords:  Aqueous humor; SARS-CoV-2; vitreous humor

Mesh:

Substances:

Year:  2021        PMID: 34427253      PMCID: PMC8544035          DOI: 10.4103/ijo.IJO_820_21

Source DB:  PubMed          Journal:  Indian J Ophthalmol        ISSN: 0301-4738            Impact factor:   1.848


SARS-CoV-2 (causative virus for COVID-19) is known to be present in tears and in the ocular surface, which might be a potential source of spread.[123] Angiotensin-converting enzyme 2 (ACE2), the receptor for SARS-CoV-2, has been detected in the aqueous humor.[4] Cornea and conjunctival epithelial cells are known to express the SARS-CoV-2 receptors ACE2 and TMPRSS2 (transmembrane serine protease 2), which help the virus enter the cell.[56] The whistleblower ophthalmologist from China, Li Wenliang, probably got infected with SARS-CoV-2 from a female glaucoma patient to which he, unfortunately, succumbed later.[7] Potential sources of infection of SARS-CoV-2 from the eye include ocular surface, tear, and retrograde transport of virus from nasal cavity via nasolacrimal duct.[8] However, literature was lacking regarding the presence or absence of SARS-CoV-2 in intraocular fluids until recently.[910] This is specifically important as cataract surgery is a known aerosol-generating procedure[11] and may potentially spread the infection in the operating room. Recently, List et al. could not find qRT-PCR evidence of SARS-CoV-2 in the aqueous and vitreous humor of 16 patients who had died of respiratory failure due to COVID-19 infection.[9] In this pilot study, we aimed to determine whether the SARS-CoV-2 viral nucleotide is present in the aqueous and vitreous humor of COVID-19 patients who underwent emergency ocular surgery.

Methods

A cross-sectional study was conducted from May 2020 to February 2021 at a tertiary eye center attached to a COVID-19-facility hospital in North India. Ethical clearance was obtained from the institutional research and ethics committee, and the study was conducted following the tenets of the Declaration of Helsinki. Consecutive patients presenting to the facility, in whom an ophthalmic surgical intervention was planned, were subjected to naso-oropharyngeal reverse transcription-polymerase chain reaction (RT-PCR) test for SARS-CoV-2. All laboratory-confirmed cases with positive RT-PCR tests were evaluated for the ophthalmic condition and were triaged according to RANZCO COVID-19 triage guidelines 2020.[12] In cases with no considerable risk of loss of vision or general health without being operated on, the surgery was deferred. Ophthalmic emergencies requiring emergent surgical interventions were enrolled for the study [Fig. 1]. Patients requiring extraocular surgical intervention were excluded [Table 1].
Figure 1

Flowchart depicting the study design. RT-PCR = Reverse transcription-polymerase chain reaction; COVID-19 = Coronavirus disease 2019, RANZCO = Royal Australian and New Zealand College of Ophthalmologists, OTCG = Ocular trauma classification group, VTM = viral transport media

Table 1

Demographic data, clinical characteristics, surgical details, and reverse-transcriptase polymerase chain reaction results of patients

S. No.1234567
Age (years)942425414324
SexMMFMMMM
DiagnosisRE Corneal LacerationRE Corneoscleral LacerationRE Corneoscleral lacerationLE Intrastromal wooden foreign body with hypopyonRE Self sealed corneal tear with endophthalmitisLE Corneoscleral lacerationRE Corneal laceration with lens matter in the anterior chamber
Mode of InjuryKite string injuryRoad traffic accidentRoad traffic accidentThorn injuryThorn injuryRoad traffic accidentGlass injury
Type/ZoneB/IB/IIB/IIC/IB/IB/IIB/I
Visual acuity5/200HMCFPL+20/200HMCF1/200HMCF
Visual acuity in other eye20/2020/20020/202/20020/2020/20No PL
Surgical InterventionCorneal laceration repairCorneoscleral laceration repairCorneoscleral laceration repairForeign body removal + AC wash + Intracameral VoriconazoleIntravitreal antibioticsCorneoscleral laceration repairCorneal laceration repair with lens aspiration
AnesthesiaGALALATAGALAGA
Interval between trauma & surgery36 h72 h48 h72 h96 h72 h36 h
Surgical time20 min25 min30 min12 min4 min25 min30 min
ComorbiditiesNilAsthma, DMNilCAD, HTNilNilNil
Systemic symptomsNilCough, SOBNilSore throat, feverNilNilNil
Duration of symptoms-4 days-3 days---
NP-OP Swab RT-PCR Ct value23172719263020
Aqueous tap RT-PCRNegativeNegativeNegativeNegativeNegativeNegativeNegative
Vitreous tap RT-PCR-NegativeNegativeNegativeNegativeNegative-
Follow-up (weeks/clinical outcome)10/Asymptomatic8/Pneumonitis12/Asymptomatic6/Recovered8/Asymptomatic6/Asymptomatic12/Asymptomatic

RE=Right eye, LE=Left eye, HMCF=Hand movements close to face, PL=Perception of light, GA=General anesthesia, LA=Local anesthesia, TA=Topical anesthesia, h=Hours, min=Minutes, DM=Diabetes mellitus, CAD=Coronary artery disease, HT=Hypertension, SOB=Shortness of breath, NP-OP=Nasopharyngeal-oropharyngeal, RT-PCR=Reverse transcription-polymerase chain reaction, Ct=Cycle threshold , M=Male, F=Female, Ac=Anterior chamber

Flowchart depicting the study design. RT-PCR = Reverse transcription-polymerase chain reaction; COVID-19 = Coronavirus disease 2019, RANZCO = Royal Australian and New Zealand College of Ophthalmologists, OTCG = Ocular trauma classification group, VTM = viral transport media Demographic data, clinical characteristics, surgical details, and reverse-transcriptase polymerase chain reaction results of patients RE=Right eye, LE=Left eye, HMCF=Hand movements close to face, PL=Perception of light, GA=General anesthesia, LA=Local anesthesia, TA=Topical anesthesia, h=Hours, min=Minutes, DM=Diabetes mellitus, CAD=Coronary artery disease, HT=Hypertension, SOB=Shortness of breath, NP-OP=Nasopharyngeal-oropharyngeal, RT-PCR=Reverse transcription-polymerase chain reaction, Ct=Cycle threshold , M=Male, F=Female, Ac=Anterior chamber A detailed history regarding the cause and duration of injury, COVID-19 disease-related symptoms, and presence of systemic comorbidities was recorded. X-ray orbit was done in all cases of open globe injuries to rule out retained intraocular foreign body. The extent of injury in terms of type, zone, and grade was noted as per the “Ocular Trauma Classification Group” recommendations.[13] Written informed consent was obtained from all patients enrolled in the study. All surgeries were done with full personal protective equipment and by following standard safety measures for operating upon a COVID-19 patient.[14]

Aqueous tap

Aqueous tap was collected in those cases where entry into the anterior chamber was required to perform intraocular surgery and/or to decrease the intraocular pressure prior to injecting intravitreal antibiotics. The eye was cleaned with 5% povidone-iodine. Anterior chamber paracentesis was done using an insulin syringe and a 30 G needle. The needle was inserted through the limbus and 0.1 ml of fluid was withdrawn. The sample was inoculated in a viral transport medium (VTM) and was sent for RT-PCR analysis.

Vitreous tap

The vitreous tap was collected in patients who underwent primary repair after 48 hours of injury and/or who had clinical signs of endophthalmitis. A 27 G needle attached to an insulin syringe was inserted through the pars plana 4 mm behind the limbus perpendicular to the sclera and 0.1 mL of vitreous was aspirated. The vitreous aspirate was divided into two portions of 0.05 mL each. One portion was sent for microbiological investigations, including Gram stain, KOH 10%, and bacterial and fungal cultures. The other portion was inoculated in VTM and was sent for RT-PCR. Intravitreal vancomycin 1 mg/0.1 mL and ceftazidime 2.25 mg/0.1 mL mg were injected after the vitreous tap. All samples were collected and labeled in separate VTMs and were transported to the institutional lab facility maintaining the recommended cold chain. The RT-PCR test was used to detect the SARS-COV-2 nucleotide. Cycle threshold (Ct) for E gene ≤35 along with confirmatory results on one of the two target genes [RNA-dependent RNA polymerase (RdRp) or open reading frame 1b (ORF1b)] was considered as positive.

Results

During the study period, a total of 132 patients presenting to the facility were found positive on naso-oropharyngeal RT-PCR test for SARS-CoV-2 preoperatively. Surgery was deferred in 122 patients following RANZCO COVID-19 triage guidelines.[12] Three patients undergoing extraocular surgical intervention were excluded. Seven patients with ocular trauma were studied [Table 1]. The mean age (± standard deviation) was 31.8 (±19.2) years. There were six males and one female. Two patients had systemic comorbidities. Five patients were asymptomatic and two patients had symptoms of mild COVID-19 disease. The mean Ct value of E gene on naso-oropharyngeal RT-PCR was 23.14 ± 4.7. The mean time interval between trauma to surgical intervention was 61.7 hours. The mean duration of surgery was 20.85 ± 9.7 minutes. The surgical intervention included repair of corneal or corneoscleral laceration in five patients, removal of intracorneal wooden foreign body in one patient, and intravitreal antibiotics injection for post-traumatic endophthalmitis in one patient. Aqueous tap was collected in seven and vitreous tap was collected in five patients. Three patients underwent surgical intervention under peribulbar block, general anesthesia was used in three patients, and two patients underwent surgery under topical anesthesia [Table 1]. None of the aqueous or vitreous samples was positive for SARS-CoV-2 viral nucleotide on RT-PCR. The members of the surgical and anesthesia team followed isolation protocol post-surgery and no one developed COVID-19-related symptoms at 6 weeks. The mean follow-up of the patients was 8.85 ± 2.5 weeks. Five patients remained asymptomatic, one patient recovered completely from mild COVID-19 disease and one patient developed pneumonitis at 8-week follow-up.

Discussion

With the ongoing COVID-19 pandemic, the surgical practices among ophthalmologists across the globe are resuming. There are many uncertainties and speculations regarding the ocular transmission of SARS-CoV-2. Studies on various laboratory models have been done to determine its transmission through aerosol-generating surgeries such as phacoemulsification.[11] Nevertheless, a definite lacuna of knowledge existed regarding the intraocular presence of this virus until very recently.[9] List and colleagues performed quantitative RT-PCR for RdRp (qRT-PCR) for SARS-CoV-2 on postmortem aqueous and vitreous samples of 16 patients who died due to complications of COVID-19. They did not find evidence of the presence of SARS-CoV-2 in any of these samples.[9] However, the effect of time after death and sample collection on the positivity of samples for SARS-CoV-2 needs further exploration. Miner et al. showed that SARS-CoV-2 failed to replicate in the human cornea, though the receptor for SARS-CoV-2, ACE2 is present in the cornea.[15] Sawant et al.[10] evaluated 20 postmortem eyes from 10 donors who were COVID-19 positive. Three vitreous swabs, five posterior corneal, and one anterior corneal sample showed the presence of SARS-CoV-2 RNA [phosphoprotein gene (N1 and N2 regions)] on RT-PCR.[10] The corneal epithelium showed SARS-CoV-2 envelope and spike proteins.[10] To the best of our knowledge, no study to date evaluated the intraocular fluids for the presence of SARS-CoV-2 in live humans. Our study did not find any laboratory evidence of the SARS-CoV-2 virus in the intraocular fluid of COVID-19 patients. Being an immune-privileged site, the eye is known to harbor viruses. Varkey et al.[16] and Gonzales et al.[17] detected viable ebolavirus and rubella virus, respectively, from the aqueous humor. However, these patients presented with uveitis in the convalescent phase. In our series, the samples were obtained during the active phase of COVID-19 infection. The presence of SARS-CoV-2 in body fluids including tears has been predicted to be associated with viral load and disease severity, as indicated by the Ct values of naso-oropharyngeal RT-PCR.[2] In our series, though there were no patients with severe COVID-19 illness, the mean Ct value was 23.14 ± 4.7, which indicates a significant viral load. As demonstrated in the viral culture studies, the infectivity of SARS-CoV-2 has been observed for the Ct value <24.[18]

Conclusion

SARS-CoV-2 was not detected by RT-PCR in aqueous or vitreous humor of asymptomatic and mild COVID-19 patients in our pilot study. Future studies with a larger sample size are needed to further explore the presence of SARS-CoV-2 in intraocular fluids.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.
  16 in total

1.  Immunohistochemical Study of SARS-CoV-2 Viral Entry Factors in the Cornea and Ocular Surface.

Authors:  Heidi Roehrich; Ching Yuan; Joshua H Hou
Journal:  Cornea       Date:  2020-12       Impact factor: 2.651

2.  A system for classifying mechanical injuries of the eye (globe). The Ocular Trauma Classification Group.

Authors:  D J Pieramici; P Sternberg; T M Aaberg; W Z Bridges; A Capone; J A Cardillo; E de Juan; F Kuhn; T A Meredith; W F Mieler; T W Olsen; P Rubsamen; T Stout
Journal:  Am J Ophthalmol       Date:  1997-06       Impact factor: 5.258

3.  Evaluation of coronavirus in tears and conjunctival secretions of patients with SARS-CoV-2 infection.

Authors:  Jianhua Xia; Jianping Tong; Mengyun Liu; Ye Shen; Dongyu Guo
Journal:  J Med Virol       Date:  2020-03-12       Impact factor: 2.327

4.  Reducing visible aerosol generation during phacoemulsification in the era of Covid-19.

Authors:  Kieren Darcy; Omar Elhaddad; Asaf Achiron; Johannes Keller; Duncan Leadbetter; Derek Tole; Sidath Liyanage
Journal:  Eye (Lond)       Date:  2020-06-26       Impact factor: 3.775

5.  Association of Ocular Inflammation and Rubella Virus Persistence.

Authors:  John A Gonzales; Armin Hinterwirth; Jessica Shantha; Kaidi Wang; Lina Zhong; Susie L Cummings; Ying Qian; Michael R Wilson; Nisha R Acharya; Thuy Doan
Journal:  JAMA Ophthalmol       Date:  2019-04-01       Impact factor: 7.389

6.  Ophthalmologists Are More Than Eye Doctors-In Memoriam Li Wenliang.

Authors:  Richard K Parrish; Michael W Stewart; Sarah L Duncan Powers
Journal:  Am J Ophthalmol       Date:  2020-03-09       Impact factor: 5.258

7.  The evidence of SARS-CoV-2 infection on ocular surface.

Authors:  Xian Zhang; Xuhui Chen; Liwen Chen; Chaohua Deng; Xiaojing Zou; Weiyong Liu; Huimin Yu; Bo Chen; Xufang Sun
Journal:  Ocul Surf       Date:  2020-04-11       Impact factor: 5.033

8.  Surgery in COVID-19 patients: operational directives.

Authors:  Federico Coccolini; Gennaro Perrone; Massimo Chiarugi; Francesco Di Marzo; Luca Ansaloni; Ildo Scandroglio; Pierluigi Marini; Mauro Zago; Paolo De Paolis; Francesco Forfori; Ferdinando Agresta; Alessandro Puzziello; Domenico D'Ugo; Elena Bignami; Valentina Bellini; Pietro Vitali; Flavia Petrini; Barbara Pifferi; Francesco Corradi; Antonio Tarasconi; Vittoria Pattonieri; Elena Bonati; Luigi Tritapepe; Vanni Agnoletti; Davide Corbella; Massimo Sartelli; Fausto Catena
Journal:  World J Emerg Surg       Date:  2020-04-07       Impact factor: 5.469

9.  Prevalence of SARS-CoV-2 in human post-mortem ocular tissues.

Authors:  Onkar B Sawant; Sneha Singh; Robert Emery Wright; Kayla M Jones; Michael S Titus; Eugene Dennis; Eric Hicks; Parag A Majmudar; Ashok Kumar; Shahzad I Mian
Journal:  Ocul Surf       Date:  2020-11-08       Impact factor: 5.033

10.  HSV-1 and Zika Virus but Not SARS-CoV-2 Replicate in the Human Cornea and Are Restricted by Corneal Type III Interferon.

Authors:  Jonathan J Miner; Derek J Platt; Cyrus M Ghaznavi; Pallavi Chandra; Andrea Santeford; Amber M Menos; Zhenyu Dong; Erin R Wang; Wei Qian; Elysse S Karozichian; Jennifer A Philips; Rajendra S Apte
Journal:  Cell Rep       Date:  2020-11-03       Impact factor: 9.423

View more
  2 in total

1.  Response to comments on: Evaluating the presence of SARS-CoV-2 in the intraocular fluid of COVID-19 patients.

Authors:  Maya Hada; Koushik Tripathy
Journal:  Indian J Ophthalmol       Date:  2022-03       Impact factor: 2.969

2.  Severe acute respiratory syndrome Corona virus and intraocular fluid sampling.

Authors:  Srinivasan Sanjay; Venkata Ramana Anandula; Padmamalini Mahendradas; Ankush Kawali; Rohit Shetty
Journal:  Indian J Ophthalmol       Date:  2021-12       Impact factor: 1.848

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.